Moc-L-Tert-Leucine CAS 162537-11-3 Puritas ≥99.0% (HPLC) Atazanavir Factory medium
Manufacturer Supple cum High puritate et stabulo Quality
Nomen chemicum: Moc-L-Tert-Leucine
CAS: 162537-11-3
Intermedia Atazanavir HIV-1 Protease Inhibitor
High Quality, Commercial Production
Nomen chemicum | Moc-L-Tert-Leucine |
Synonyma | Methoxycarbonyl-L-tert-Leucine;N-(Methoxycarbonyl)-tert-Leucine;Atazanavir Related Compone A |
CAS Number | 162537-11-3 |
CATTUS Number | RF-PI289 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C8H15NO4 |
M. Pondus | 189.21 |
Liquescens punctum | 109℃ |
Density | 1.126 g/cm3 |
Ferveret | 320.9℃ ad 760 mmHg |
Solubilitas | Solutum in Ethyl acetate et Methanol |
Shipping Condition | Uit sub Ambient Temperature |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | White ad Off-White Crystal |
Lepidium sativum Methodi | HPLC |
Puritas / Analysis Methodo | ≥99.0% (HPLC) |
Moc-L-Tle-Tle-OH | ≤0.30% |
L-Moc-Dimer | ≤0.30% |
L-Tle-OH | ≤0.10% |
Methoxycarbonyl-L-Valine | ≤0.10% |
N-Acetyl-L-tert-Leucine | ≤0.05% |
Singula Unkown Impuritas | ≤0.30% |
Totalis immunditias | ≤1.0% |
Enantiomer Content | ≤0.10% (Per Chiral HPLC) |
Aqua Content | ≤0.50% (By KF) |
Damnum in Siccatio | ≤0.50% |
Residere in Ignition | ≤0.20% |
Metalla gravis | ≤10ppm |
Consuetudinem | Amino acid;Medium Atazanavir (CAS 198904-31-3); |
sarcina: Utrem, aluminium foil, sacculum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Lucem protege, humorem.
Shanghai Ruifu Chemical Co., Ltd. est primarium fabricae et supplementi Moc-L-Tert-Leucine (CAS 162537-11-3) magna qualitate.MOC-L-Tert-Leucine est genus acidum amino derivativum.Intermedium utilissimum est ad efficientem synthesim HIV protease inhibitoris Atazanavir (CAS 198904-31-3) necnon Atazanavir sulphate (CAS 229975-97-7).
Atazanavir est agens antiretrovirale quod FDA probatum est usui in compositione cum aliis anti-RTagentis ad curationem infectionis HIV.Medicamentum in inhibitoribus RT coniunctum semper adhibetur.Atazanavir inhibitor est protease HIV-1 (EC50=2.6 nM).In cellulis separatis, effectus antivirales mediocriter synergisticos additivos habet cum aliis medicamentis antiretroviralibus coniunctos.Quam ob rem communiter in vivo in compositione curationis HIV-1 infectio adhibetur.